PARP1 and ovarian carcinoma: The findings suggest that downregulation of KLF5 can enhance the susceptibility of PARPi-resistant ovarian cancer cells to PARP inhibitors, while upregulation of KLF5 can promote resistance of PARPi-sensitive ovarian cancer cells to PARP inhibitors.